Abstracts tagged "spondyloarthritis"

Abstract Number: L02 • ACR Convergence 2022
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Christopher Ritchlin¹, Laura Coates², Iain McInnes³, Philip J. Mease⁴, Joseph Merola⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Laure Gossec⁸, Alice Gottlieb⁹, Diamant Thaci¹⁰, Barbara Ink¹¹, Deepak Assudani¹¹, Rajan Bajracharya¹¹, Vish Shende¹¹, Jason Coarse¹² and Robert Landewé¹³, ¹University of Rochester Medical Center, Rochester, NY, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ³College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁵Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁶University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁷Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁸Sorbonne Universités, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière, Rheumatology Department, Paris, France, Paris, France, ⁹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹¹UCB Pharma, Slough, United Kingdom, ¹²UCB Pharma, Raleigh, NC, ¹³Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuyderland MC, Heerlen, Netherlands
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy in joints and…
Abstract Number: L14 • ACR Convergence 2022
Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
Xenofon Baraliakos¹, Atul Deodhar², Désirée van der Heijde³, Marina Magrey⁴, Walter Maksymowych⁵, Tetsuya Tomita⁶, Huji Xu⁷, Marga Oortgiesen⁸, Ute Massow⁹, Carmen Fleurinck¹⁰, Alicia M Ellis⁸, Tom Vaux¹¹, Julie Shepherd-Smith¹¹, Alexander Marten⁹ and Lianne S Gensler¹², ¹Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, ²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, US, Richfield, OH, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Graduate School of Health Science, Morinomiya University of Medical Science, Osaka City, Osaka City, Osaka, Japan, ⁷Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China (People's Republic), ⁸UCB Pharma, Morrisvile, NC, ⁹UCB Pharma, Monheim am Rhein, Nordrhein-Westfalen, Germany, ¹⁰UCB Pharma, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL‑17A. In the phase 3 BE MOBILE 1 and 2…
Abstract Number: L15 • ACR Convergence 2022
Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study
Xenofon Baraliakos¹, Mikkel Østergaard², Denis Poddubnyy³, Désirée van der Heijde⁴, Atul Deodhar⁵, Pedro M. Machado⁶, Victoria Navarro-Compán⁷, Kay Geert Hermann⁸, Mitsumasa Kishimoto⁹, Eun Young Lee¹⁰, Lianne S Gensler¹¹, Uta Kiltz¹, Marco Eigenmann¹², Patricia Pertel¹³, Aimee Readie¹⁴, Hanno B. Richards¹², Brian Porter¹⁵ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ³Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁶Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁷Department of Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ⁸Department of Radiology, University Hospital Charité - Campus Mitte, Charitéplatz, Berlin, Germany, ⁹Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, ¹¹Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ¹²Novartis Pharma AG, Basel, Switzerland, ¹³Novartis Pharma AG, Reinach, Switzerland, ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁵Novartis Pharmaceuticals Corporation, Far Hills, NJ
Background/Purpose: Biologics are clinically efficacious in patients (pts) with axial spondyloarthritis (axSpA) including radiographic axSpA (r-axSpA). Limited data exist on the effect of biologics in…
Abstract Number: 0057 • ACR Convergence 2022
Accelerating AxSpA Diagnosis: Exploring At-home Self-sampling, Symptom Checkers, Medical Student-visits and Asynchronous Report-based Assessment
Hannah Labinsky¹, Sophie von Rohr², Maria Gabriella Raimondo³, Ekaterina Vogt⁴, Britta Horstmann², Isabel Gehring⁵, Jessica Rojas-Restrepo⁵, Fabian Proft⁶, Felix Mühlensiepen⁷, Daniela Bohr², Georg Schett⁸, Andreas Ramming³ and Johannes Knitza³, ¹Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Thermo Fisher Scientific, Freiburg, Germany, ⁵Thermo Fisher Scientific, Freiburg, ⁶Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁷Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Rüdersdorf, ⁸Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: The growing shortage of rheumatologists threatens adequate rheumatological care. The diagnostic delay for axial spondyloarthritis (axSpA) is particularly long, ranging between 3 to 11…
Abstract Number: 0408 • ACR Convergence 2022
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Philip C. Robinson¹, Walter P Maksymowych², Lianne Gensler³, Martin Rudwaleit⁴, Bengt Hoepken⁵, Lars Bauer⁵, Thomas Kumke⁵, Mindy Kim⁶ and Atul Deodhar⁷, ¹University of Queensland School of Clinical Medicine, Brisbane, Australia, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Smyrna, GA, ⁷Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Certolizumab pegol (CZP) has demonstrated clinical efficacy in patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (OSI) during the…
Abstract Number: 0545 • ACR Convergence 2022
Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatment in Patients with Non-radiographic Spondylarthritis Who Achieved Inactive Disease: Efficacy and Safety Results from a Placebo-Controlled, Randomized Withdrawal and Retreatment Study (GO-BACK)
Cindy Weinstein¹, Paula Sliwinska-Stanczyk², Tomas Hala³, Marina Stanislav⁴, Anjela Tzontcheva⁵, Ruji Yao¹, Yuliya Berd¹, Sean Curtis¹ and George Philip¹, ¹Merck & Co., Inc., Rahway, NJ, ²Reumatika Centrum Reumatologii, Warsaw, Poland, ³Center for Clinical and Basic Research, Pardubice, Czech Republic, ⁴Vladimirsky Moscow Regional Scientific Institution, Moscow, Russia, ⁵MSD Switzerland, Zürich, Switzerland
Background/Purpose: Non-radiographic axial spondyloarthrits (nr-axSpA) is a rheumatic disease that is predominantly associated with chronic back pain and stiffness.1 Results from the Phase III GO-AHEAD…
Abstract Number: 1020 • ACR Convergence 2022
Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review
Vartika Kesarwani¹, Stephanie Sinnappan², M. Elaine Husni³, Michael Weisman⁴ and Joerg Ermann⁵, ¹University of Connecticut, Farmington, CT, ²Brigham and Women's Hospital, Boston, MA, ³Cleveland Clinic, Cleveland, OH, ⁴Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Extra-articular manifestations of spondyloarthritis (SpA) may precede the development of articular features. Patients seen in dermatology, gastroenterology, and ophthalmology clinics for psoriasis, IBD, or…
Abstract Number: 1165 • ACR Convergence 2022
Pathogenicity of IL-17 Producing Cells in HLA-B27 Transgenic Rat Model of Spondyloarthritis
Marie Beaufrère¹, Manon Jacoutot¹, Amel Ait Ali Said¹, Roula Said-Nahal², Gina Cosentino³, Chiara Rizzo³, Maxime Breban⁴ and Simon Glatigny⁴, ¹Paris Saclay University / INSERM 1173, Montigny-le-Bretonneux, France, ²Rheumatology Division - Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France, ³INSERM 1173, Montigny-le-Bretonneux, France, ⁴1INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France
Background/Purpose: Spondylarthritis (SpA) is a group of chronic inflammatory disorders with osteoarticular and extraarticular symptoms, including colitis, highly associated with the human leukocyte antigen (HLA)…
Abstract Number: 1511 • ACR Convergence 2022
Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic Arthritis
Dafna Gladman¹, Ghaydaa Aldabie², Fangya Ma³, Mitchell Sutton⁴, Ker-Ai Lee³ and Richard Cook³, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³University of Waterloo, Waterloo, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: The majority of patients with PsA present with skin manifestations first. Several studies have examined the relationship between activity/severity of skin and joint manifestations,…
Abstract Number: 2119 • ACR Convergence 2022
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
M. Elaine Husni¹, Philip J Mease², Joseph Merola³, Frank Behrens⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, William Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and Laure Gossec¹², ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁵University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Sorbonne Université, Paris, France
Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1…
Abstract Number: 0373 • ACR Convergence 2022
Factors Associated with Adverse Outcomes in Uveitis Related to Spondylarthritis (SpA-U)- Development of a Prognostic Outcome Score in Patients with SpA-U
Cristiana Sieiro Santos¹, Isabel Sendino Tenorio¹, Carolina Álvarez Castro¹, Clara Moriano Morales², Miguel Cordero Coma¹ and Elvira Díez Álvarez¹, ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital León, León, Spain
Background/Purpose: Uveitis is the most frequent extra-articular manifestation of spondylarthritis (SpA), characterized by a sudden onset, often unilateral, anterior and recurrent and may be the…
Abstract Number: 0409 • ACR Convergence 2022
Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
Philip J Mease¹, Atul Deodhar², Maxime Dougados³, Maureen Dubreuil⁴, Marina Magrey⁵, Helena Marzo-Ortega⁶, Martin Rudwaleit⁷, Christine de la Loge⁸, Alicia Ellis⁹, Carmen Fleurinck¹⁰, Marga Oortgiesen¹¹, Vanessa Taieb¹² and Lianne Gensler¹³, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Oregon Health & Science University, Portland, OR, USA, Portland, OR, ³Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁴Department of Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Case Western Reserve University, University Hospitals, Richfield, OH, ⁶Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁸UCB Pharma, Brussels, Belgium, ⁹UCB Pharma, Raleigh, ¹⁰UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²UCB Pharma, Colombes, France, ¹³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ improved signs and symptoms and reduced disease activity…
Abstract Number: 0547 • ACR Convergence 2022
Profiling of Systemic Immune Responses in Axial Spondyloarthritis Patients Reveals Strikingly Distinct Cellular and Molecular Mechanisms of Action of IL-17A Inhibitors and TNF-Blockers
Nicolas Rosine¹, Surya Koturan¹, Vincent Guillemot², Claire Leloup¹, Fanni Veress¹, Tharshana Stephen¹, Hanan Yahia-Cherbal¹, Jérémie SELLAM³, Francis Berenbaum⁴, Natalia Pietrosemoli¹, Elisabetta Bianchi¹, Corinne MIceli⁵ and Lars Rogge¹, ¹Institut Pasteur, Paris, France, ²Institut Pasteur, Paris, Ile-de-France, France, ³Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ⁴Sorbonne University - Saint-Antoine hospital, Paris, France, ⁵APHP, Paris, France
Background/Purpose: IL-17A inhibitors (IL-17i) and TNF-inhibitors (TNFi) are currently the only biologic drugs available to treat axial spondyloarthritis (axSpA). While several studies have provided mechanistic…
Abstract Number: 1022 • ACR Convergence 2022
Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis
Walter P Maksymowych¹, Anna Hadsbjerg², Mikkel Østergaard³, Raphael Micheroli⁴, Susanne J. Pedersen⁵, Adrian Ciurea⁶, Nora Vladimirova², Michael Nissen⁷, Kristyna Bubova⁸, Stephanie Wichuk⁹, Manouk de Hooge¹⁰, Ashish J Mathew¹¹, Karlo Pintaric¹², Monika gregova¹³, Ziga Snoj¹², Marie Wetterslev¹⁴, Karel Gorican¹⁵, Joel Paschke¹⁶, Iris Eshed¹⁷ and Robert G Lambert⁹, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁴University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, ⁵Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁶University Hospital Zurich, Zürich, Switzerland, ⁷Hopitaux Universitaires de Genève, Geneva, Switzerland, ⁸First Faculty of Medicine, Charles University,, Prague, Czech Republic, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Ghent University Hospital, Luxembourg, Luxembourg, ¹¹Rigshospitalet, Copenhagen, Denmark, ¹²Radiology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹³Institue of Rheumatology, Prague, ¹⁴Rigshospitalet, Copenhagen, Glostrup, Denmark, ¹⁵MSK radiology unit, Radiology section – Diagnostic department, Geneva University Hospitals, Geneva, Switzerland, ¹⁶CARE Arthritis LTD, Edmonton, AB, Canada, ¹⁷Sheba Medical Center, Tel Aviv, Israel
Background/Purpose: Quantification of inflammatory and structural lesions in the sacroiliac joints (SIJ) on MRI scans from patients with axial spondyloarthritis (axSpA) has a growing list…
Abstract Number: 1243 • ACR Convergence 2022
The Impact of MRI Slice Thickness on the Detection of Spinal Syndesmophytes in Axial Spondyloarthritis
Kalliopi Klavdianou¹, Alexaner Dieter Mewes², Styliani Tsiami³, Philipp Sewerin⁴ and Xenofon Baraliakos⁵, ¹'Asklepieion' General Hospital, Department of Rheumatology, Voula, Athens, Greece, ²University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, Dusseldorf, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Conventional radiographs (CR) are the gold standard for detecting syndesmophytes in axial Spondyloarthritis (axSpA), mainly because magnetic resonance imaging (MRI) is not able to…

1
2
3
…
24
Next Page »